Advertisement
Review Article| Volume 30, ISSUE 3, P557-563, September 2010

First-Trimester Genetic Counseling: Perspectives and Considerations

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Spencer K.
        • Souter V.
        • Tul N.
        • et al.
        A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
        Ultrasound Obstet Gynecol. 1999; 13: 231-237
        • Kagan K.O.
        • Wright D.
        • Valencia C.
        • et al.
        Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.
        Humanit Rep. 2008; 23: 1968-1975
        • Atzei A.
        • Gajewska K.
        • Huggon I.
        • et al.
        Relationship between nuchal translucency thickness and prevalence of major cardiac defects in fetuses with normal karyotype.
        Ultrasound Obstet Gynecol. 2005; 26: 154-157
        • Souka A.P.
        • Von Kaisenberg C.S.
        • Hyett J.A.
        • et al.
        Increased nuchal translucency with normal karyotype.
        Am J Obstet Gynecol. 2005; 192: 1005-1021
        • Spencer K.
        • Cowans N.
        • Avgidou K.
        • et al.
        First-trimester biochemical markers of aneuploidy and the prediction of small-for-gestational age fetuses.
        Ultrasound Obstet Gynecol. 2008; 31: 15-19
        • Spencer K.
        • Cowans N.
        • Molina F.
        • et al.
        First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery.
        Ultrasound Obstet Gynecol. 2008; 31: 147-152
        • Spencer K.
        • Cowans N.
        • Nicolaides K.H.
        Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia.
        Prenat Diagn. 2008; 28: 7-10
        • Poon L.
        • Maiz N.
        • Valencia C.
        • et al.
        First trimester maternal serum PAPP-A and pre-eclampsia.
        Ultrasound Obstet Gynecol. 2009; 33: 23-33
        • Khaw A.
        • Kametas N.
        • Turan O.
        • et al.
        Maternal cardiac function and uterine artery Doppler at 11–14 weeks in the prediction of pre-eclampsia in nulliparous women.
        BJOG. 2008; 115: 369-376
        • Kagan K.O.
        • Cicero S.
        • Staboulidou I.
        • et al.
        Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11–13 weeks of gestation.
        Ultrasound Obstet Gynecol. 2009; 33: 259-264
        • Maiz N.
        • Valencia C.
        • Kagan K.O.
        • et al.
        Ductus venosus Doppler in screening for trisomies 21, 18 and 13 and Turner syndrome at 11–13 weeks of gestation.
        Ultrasound Obstet Gynecol. 2009; 33: 512-517
        • Kagan K.O.
        • Valencia C.
        • Livanos P.
        • et al.
        Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11+0 to 13+6 weeks of gestation.
        Ultrasound Obstet Gynecol. 2009; 33: 18-22
        • Falcon O.
        • Faiola S.
        • Huggon I.
        • et al.
        Fetal tricuspid regurgitation at the 11 + 0 to 13 + 6-week scan: association with chromosomal defects and reproducibility of the method.
        Ultrasound Obstet Gynecol. 2006; 27: 609-612
        • Falcon O.
        • Auer M.
        • Gerovassili A.
        • et al.
        Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
        Ultrasound Obstet Gynecol. 2006; 27: 151-155
        • Spencer K.
        • Spencer C.E.
        • Power M.
        • et al.
        Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one stop clinic: a review of three years prospective experience.
        BJOG. 2003; 110: 281-286
        • Dagklis T.
        • Plasencia W.
        • Maiz N.
        • et al.
        Choroid plexus cyst, intracardiac echogenic focus, hyperechogenic bowel and hydronephrosis in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks.
        Ultrasound Obstet Gynecol. 2008; 31: 132-135
        • Spencer K.
        • Kagan K.
        • Nicolaides K.H.
        Screening for trisomy 21 in twin pregnancies in the first trimester: an update of the impact of chorionicity on maternal serum markers.
        Prenat Diagn. 2008; 28: 49-52
        • Liao A.
        • Heath V.
        • Kametas N.
        • et al.
        First-trimester screening for trisomy 21 in singleton pregnancies achieved by assisted reproduction.
        Humanit Rep. 2001; 16: 1501-1504